Brief: Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism
02/09/2025 13:25
Rezolute Inc RZLT.O: REZOLUTE ANNOUNCES ALIGNMENT WITH FDA ON STREAMLINED DESIGN FOR ONGOING PHASE 3 TRIAL OF ERSODETUG IN TUMOR HYPERINSULINISM REZOLUTE INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026 - SEC FILING REZOLUTE INC: FDA ALSO CONFIRMED THAT REZOLUTE S PIVOTAL SUNRIZE TRIAL IN CONGENITAL HI, WHICH IS ON TRACK TO REPORT TOPLINE RESULTS IN DECEMBER 2025 Source text: [ID:n0001104659-25-085892] Further company coverage: RZLT.O